Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Oral Oncology|November 21, 2016
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX studyElvira Del Barco Morillo, Ricard Mesía, Juan Carlos Adansa Klain, et al.
Pediatric Blood & Cancer|March 26, 2026
European Standard Clinical Practice Recommendations for Cutaneous Melanoma in Children and AdolescentsLuca Bergamaschi, Alice Indini, Ines B Brecht, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 19, 2024
Recommendations for the management of cutaneous squamous cell carcinoma: a systematic multidisciplinary Delphi consensus approachEva Muñoz Couselo, Javier Cañueto, Vanessa Jerviz Guía, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)José María Piulats, Enrique Espinosa, Luis de la Cruz Merino, et al.
Oncotargets and Therapy|November 7, 2024
Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced MelanomaGuillermo Valencia, Katia Roque, Patricia Rioja, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 1, 2024
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysisPablo Cerezuela-Fuentes, Maria Gonzalez-Cao, Teresa Puertolas, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 15, 2024
Access to melanoma drugs in Spain: a cross-sectional surveyMaria Gonzalez-Cao, Teresa Puertolas, Jose Luis Manzano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Pageof 5